Navigation Links
Xcat 50

ProductsXcat 50
Company Kubtec
Item Xcat 50
Features 
Description The desk-top XCAT 50 X-Ray System from KUBTEC is a dual capability system with the ability to provide two and three dimensional representation of the specimen under test. While the XCAT series provides volumetric reconstruction of specimen X-ray images, the micro focus source also allows the system to provide high level of detail in standard 2D images. The 50 mm x 50 mm digital detector provides image resolution at 12 bits and 10 lp/mm. The compact size and shielding allow the unit to be easily located in most environments. The fast state-of-the-art CT reconstruction software and parallel processing capability enables the user to obtain high quality images from all viewing angles in a relatively short period of time.
Info Kubtec
Customer Service: (203) 364-8544
Web site: http://www.kubtec.com

Related medicine products :

1. GeneXpert System
2. Xpert 80
3. Xpert GBS
4. Clinical Xpert™ PDA Medical Reference and Decision-Support Tool
TAG: Xcat
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products:
(Date:11/21/2008)...general membership of the Medical,Advertising Hal... their Annual,Awards Dinner to be held February 1...me Achievement Award will also be given. , ...ll of Fame are: , Ronald Pantello, who began hi...Sudler & Hennessey. In 1980 he left Sudler &am...
(Date:11/21/2008)...ases production of neural stem cells , ,...s in mice, exercise appears to reverse the decline...n with aging, Taiwanese researchers report. , T...to stave off aging appears to be due to exercise,s...ial for the production of new brain cells. , "...
(Date:11/21/2008)...e/ -- A prestigious group of physicians, nurses, a...iamsburg, VA on March 27-29, 2009 at the Williamsb... on cutting-edge therapeutic protocols, novel diag...s that impact patient care. The full program, facu...s available at www.bioconferences.com/wh , ,...
(Date:11/21/2008)...ty of Texas M. D. Anderson Cancer Center marked th... breast cancer in Panama through the Partnership f...ricas today at an event with Laura Bush, the First... Torrijos, the First Lady of Panama. , Joining...artment of State and Susan G. Komen for the Cure w...
Breaking Medicine News(10 mins):Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:Exercise Keeps the Brain Young 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...a Swedish doctor involving more than 65, 000 per...of blood sugar and the risk of developing cancer//...er, Sweden and team, who examined data from 31,304...search. The subjects had previously participated...
...a higher body mass index (BMI) tend are less likel...tion for an ischemic stroke// , according to a rep...lood to a part of the brain is blocked or reduced ...t be delivered to brain tissue. Obesity and excess...
...d dean of University of Massachusetts Medical Scho...o health reasons//. It was reported that he has de...sible for the merger of state hospital and the pri...et up the $ 100 million research lab there. In 198...
...ently accounts for one-third of the global TB burd...tion// infected by the TB bacillus. Every year, ...0 die from it, resulting in 1,000 deaths every day...than other infectious diseases, it has been report...
Other Medicine News:Health News:Beware of High Sugar Levels Even If You are Not Diabetic 2Health News:Stroke Patients With High BMI Less Likely to Be Discharged After Hospitalization 2Health News:TB Incidence on Rise Among Children in Tamil Nadu, Maharashtra 2
(Date:11/19/2008)...THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCa...e Takeda Oncology Company, a subsidiary of,Takeda... announced that,enrollment in the Phase 3 MONET1 ...on with paclitaxel and carboplatin for the first-l...cer (NSCLC) has been temporarily suspended,follow...
(Date:11/19/2008)...-Triggers $5 Million Payment from Roche- , , ...- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) t... goal for its Phase 2 trial of R3487/MEM 3454, its...tive impairment associated with schizophrenia (CIA...e Phase 2 trial, triggering a $5.0 million payment...
(Date:11/18/2008)...American Lung Association,s 2008 Faces of Influenz...lies immunized against influenza; Mother and Gold ..., WASHINGTON, Nov. 18 While 78 ...nfluenza a severe and potentially life-threatening...is likely their families will get vaccinated this ...
(Date:11/12/2008)... NEW YORK, Nov. 12 A... edition of Cell will help answer the,question, wh...ressing questions in the medical research into,Par...s in the brain to die,in the first place. Answerin...use there are two nearly identical types of brain ...
Breaking Medicine Technology:Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6A Window Into Parkinson's Disease 2Antares Management Solutions Selects Hyland Softwares OnBase 13993 1Antares Management Solutions Selects Hyland Softwares OnBase 13993 2Schering Plough Announces Filing of U S Application for OTC ZEGERID 28R 29 3853 1Schering Plough Announces Filing of U S Application for OTC ZEGERID 28R 29 3853 2Schering Plough Announces Filing of U S Application for OTC ZEGERID 28R 29 3853 3Wildwood Organics Introduces Probiotic Soymilk 28TM 29 13990 1Wildwood Organics Introduces Probiotic Soymilk 28TM 29 13990 2Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 1Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 2Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 3Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 4Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 5Totality of Available Data Reaffirms PROCRIT 28R 29 28Epoetin alfa 29 Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy 1495 6